Related Experiment Video

Updated: Jun 10, 2026

Murine Heterotopic Heart Transplant Technique
10:27

Murine Heterotopic Heart Transplant Technique

Published on: July 8, 2014

TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection

Adam J Booth1, D Keith Bishop

  • 1Division of Pulmonary & Critical Care, Department of Internal Medicine, University of Michigan Medical Center, 6240 MSRBIII/0624, 1150 W Medical Center Drive, Ann Arbor, MI 48109, USA. boothaj@med.umich.edu

Immunotherapy
|July 20, 2010
PubMed

Insights

Chronic rejection after cardiac transplantation involves cardiomyocyte hypertrophy, driven by immune cytokines like IL-6. Understanding these factors is key to developing new therapies for long-term graft survival.

Area of Science:

  • Immunology
  • Cardiology
  • Transplantation Science

Background:

  • Cardiac transplantation is a vital treatment for end-stage heart failure.
  • While short-term survival has improved, chronic rejection remains a major obstacle to long-term graft success.
  • Chronic rejection is characterized by fibrosis, vascular issues, and declining graft function.

Purpose of the Study:

  • To summarize current research on the mechanisms of chronic cardiac allograft rejection.
  • To highlight the role of cardiomyocyte hypertrophy as a pathological feature.
  • To discuss the involvement of specific immune cytokines and downstream mediators.

Main Methods:

  • Review of experimental and patient studies.
  • Analysis of molecular pathways involved in chronic rejection.
  • Identification of key cytokines and fibrotic mediators.

Main Results:

  • Cardiomyocyte hypertrophy is identified as a hallmark of chronic cardiac allograft rejection.
  • The immune cytokine Interleukin-6 (IL-6) is closely linked to this pathological hypertrophy.
  • IL-6, along with TGF-beta and IL-17, promotes chronic rejection, activating mediators like CTGF that drive fibrosis.

Conclusions:

  • Contemporary findings reveal multiple factors contributing to chronic cardiac allograft rejection.
  • Elucidating the complex interplay of these factors is crucial for developing targeted therapies.
  • Further research may lead to improved long-term outcomes for heart transplant recipients.

More Related Videos

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...